Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
XORTX Therapeutics Inc. XRTX
$0.66
-$0.03 (-5.03%)
На 18:04, 12 мая 2023
Ключевые показатели
-
Marketcap
12502842.00000000
-
week52high
2.23
-
week52low
0.41
-
Revenue
-
P/E TTM
0
-
Beta
0.10766200
-
EPS
-0.55000000
-
Last Dividend
0.37500000
-
Next Earnings Date
12 мая 2023 г. в 04:00
Описание компании
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Why Is Xortx Therapeutics (XRTX) Stock Up 30% Today?
InvestorPlace
19 янв 2023 г. в 11:37
There's great news circulating about Xortx Therapeutics (NASDAQ: XRTX ) today. In a clinical study, XORLO, Xortx's orally administered brand of oxypurinol, demonstrated a “substantial increase” in bioavailability.
XORTX Announces Participation at Upcoming Investor Conferences
GlobeNewsWire
03 ноя 2022 г. в 10:15
CALGARY, Alberta, Nov. 03, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that Dr. Allen Davidoff, President and CEO, is scheduled to participate in the following upcoming investor conferences:
Why Are XORTX Therapeutics Shares Skyrocketing Today?
Benzinga
13 июл 2022 г. в 08:39
XORTX Therapeutics Inc (NASDAQ: XRTX) has announced topline results from Part 1 of the three-part Pharmacokinetics Bridging Study – XRX-OXY-101. The data showed a substantial increase in oral bioavailability of two versions of XORTX's proprietary oxypurinol formulation.
XORTX Therapeutics (XRTX) Stock: Why It Skyrocketed Over 90% Today
Pulse2
13 июл 2022 г. в 08:11
The stock price of XORTX Therapeutics Inc (NASDAQ: XRTX) skyrocketed by over 90% pre-market today. This is why.
XORTX to Present at BIO International Convention 2022
GlobeNewsWire
13 июн 2022 г. в 08:55
CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce its participation in the BIO International Convention 2022, being held June 13th through 16th, 2022. Dr. Allen Davidoff, XORTX's CEO, will present an overview on the Company, including the Company's progress to date and planned future regulatory and clinical activities.